Furthermore, in triple negative breast cancer a high mutation frequency was identified in PI3K signaling pathway-related genes, including PIK3C2G, and HER2+ breast cancer cells were sensitized to trastuzamub treatment when PIK3C2G was silenced (Lapin et al., 2014[41]; Weisman et al., 2016[87]). This evidence concerns the gene PIK3C2G and triple-negative breast carcinoma.